,21 By 2020, the FDA extended neratinib’s approval to include the treatment of advanced or metastatic ErbB2-positive breast cancer patients who had received more than two prior anti-ErbB2-based regimens in the metastatic setting, when used in combination with capecitabine.20 Here, ERBB2 is linked to breast carcinoma.